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showed improved safety and higher accuracy. Our results indicate that 
intraoperative US may have important staging implication. 
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Background: Surgery is the gold standard for cure in resectable Non-
Small-Cell Lung Cancer (NSCLC). Pneumonectomy and lobectomy 
are performed along with mediastinal lymph node dissection to allow 
pTNM staging. In other tumor types including colon and gastric cancer, 
it has been demonstrated that the number of examined lymph node is 
an independent prognostic factor of survival, whatever the lymph node 
involvement. We retrospectively analyzed 218 patients with a totally 
resected NSCLC and looked at the prognostic value of the number of 
lymph nodes examined on the resected specimen. 
Methods: Consecutive cases from 01/2001 to 12/2004 included 81% 
men, median age 61, Squamous histology 50%, Adenocarcinoma 39%. 
There were 44% pTNM stage I, 29% stage II and 27% stage III, (54% 
pN0, 30% pN1 and 16% pN2), median follow-up 38 months. Surgery 
consisted in pneumonectomy (33%), lobectomy or bilobectomy (67%). 
Only 18 patients (8.6%) received adjuvant chemotherapy.
Results: The median number of lymph nodes examined was 7 (1-48) 
(pneumonectomy, median of examined lymph nodes 10, lobectomy/
bilobectomy, 6 examined lymph nodes). Three groups were deﬁned 
according to the number of examined lymph nodes to assess a possible 
prognostic value: 0-4 (group 1), 5-8 (group 2), 9 or more(group 3). In 
the overall population, no difference was seen among the three groups 
on Relapse-Free Survival (RFS, p=0.48), Lung cancer Speciﬁc Survival 
(LCSS, p=0.44) and Overall Survival (OS, P=0.63). In stage pN1, the 
number of examined lymph nodes if less than 5 had a signiﬁcant impact 
on RFS (p=0.0003), on OS (p=0.014), and on LCSS (p=0.028). No 
difference was seen in stage pN0 and pN2. Based on the present study, 
patients resected for Stage pN1 with less than 5 lymph nodes examined 
on the resected specimen have a poor outcome, behaving as patients 
with stage pN2 and actually may be understaged: RFS 7.2 vs 7.6 
months, LCSS 23.5 vs 18.7 months, OS 21.6 vs 18.5 months in pN2 vs 
pN1 with less than 5 examined lymph nodes respectively. 
Conclusion: A minimum of 5 lymph nodes should be recommended 
for pathologic examination to provide proper staging in stage pN1 
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Purpose: Operative stress can alter the blood levels of various physi-
ologically active substances (cytokines, growth factors, etc.), and thus 
potentially affect cancer cell proliferation. How the combination of 
changes in blood levels of these substances affects cancer cells has not 
been adequate addressed. In an in vitro study we previously reported 
that human serum obtained immediately after lung resection surgery 
stimulated lung cancer cell proliferation compared to that obtained 
before surgery. Here we investigated the time course of the stimulation 
capacity of serum for cancer cell proliferation in the early postoperative 
period.
Methods: The subjects were 10 patients undergoing lung cancer surgery. 
Blood was sampled from each subject immediately before surgery and 
immediately, one day, one week, and two weeks after surgery. Serum 
derived from each blood sample was frozen and stored. EBC-1, a human 
NSCLC culture cell line, was used for the study. Cells were exposed to 
serum (collected at varying points of time before and after surgery) at a 
concentration of 10% for 48 hours. MTT assay was conducted thereafter 
to evaluate cell proliferation, with absorbance (O.D.) measured at 540 
nm (control: 630 nm) using a microplate reader. The percent stimulation 
of cell proliferation with postoperative serum compared with control 
(preoperative) serum was calculated using the formula 100 x (postopera-
tive O.D. - preoperative O.D.)/preoperative O.D.
Results: Serum collected at each time point (immediately, one day, one 
week, and two weeks) after surgery signiﬁcantly stimulated the pro-
liferation of EBC-1 compared to preoperative serum. Serum collected 
immediately after surgery showed the highest percent stimulation of 
cell proliferation, and this effect tended to decrease gradually with time 
after surgery. However, even serum collected two weeks after surgery 
still signiﬁcantly stimulated cell proliferation compared to preoperative 
serum. 
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Background: The aim of the study was to identify the common factors 
which affect survival of surgically resected non-small cell lung cancer 
(NSCLC) patients with N1 and N2 disease.
Methods: A retrospective review was performed in NSCLC patients 
who underwent primary surgical resection from Jan 2000 to Sep 2006. 
The inclusion criteria were patients with 1) pathologically conﬁrmed 
N1 and N2 disease, 2) pathologic T1 to T3 disease, 3) no history of 
neoadjuvant chemotherapy, and 4) complete mediastinal lymphad-
enectomy. During the study period 468 NSCLC patients with nodal 
metastasis were operated on in our hospital. According to the selection 
criteria, 281 patients (60.0%) were included in the study. There were 
132 patients with N1 disease (N1 group) and 149 patients with N2 dis-
ease (N2 group). The median follow-up period was 22 months (1 ~ 81 
months) and complete follow-up was possible in 269 patients (95.7%).
Results: Lobectomy was performed in 195 patients (69.4%), bilobec-
tomy in 43 (15.3%) and pneumonectomy in 43 (15.3%). Complete 
resection was possible in 274 patients (97.5%) and operative mortality 
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occurred in 5 patients (1.8%). There were more female, adenocarci-
noma patients in N2 group (p<0.05); however, T stage was not different 
between N1 and N2 groups. The number of metastatic lymph nodes and 
nodal stations were 5.6 ± 5.6 and 2.5 ± 1.4 in N2 group, which were 
signiﬁcantly higher than 2.3 ± 1.7 and 1.2 ± 0.5 of N1 group (p<0.05). 
The overall 5-year survivals of N1 and N2 groups were 62.0% and 
39.6% (p<0.05). Multivariate analysis revealed that the age and the 
number of metastatic nodal stations were signiﬁcant risk factors for 
overall survival (p<0.05), however, N2 disease was not a signiﬁcant 
risk factor. The 5-year survival of patients with 1, 2, and 3 metastatic 
nodal stations were 68.4%, 32.3%, and 0% in N1 group, and 68.2%, 
32.0%, and 15.0% in N2 group, which did not show signiﬁcant differ-
ence between N1 and N2 groups.
Conclusions: In our study, multiplicity of metastatic nodal station 
signiﬁcantly affected overall survival in NSCLC with nodal metastasis 
rather than the locations of metastatic lymph node. Worse prognosis of 
N2 disease than N1 disease was due to the high probability of multiple 
metastatic nodal stations of N2 disease.
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Background: The 5-year survival rate after complete resection of non-
small cell lung cancer has improved with the decades from 41% in the 
1970’s, to 58% in the 1980’s, 63% in the 1990’s, to 78% since 2000. 
Factors related to the improvement were analyzed. 
Method: We used the survival index to ascertain how the 5-year sur-
vival rate of patients changed with the decade according to stage of the 
disease. The survival index was calculated by multiplying the propor-
tion of cases by the 5-year survival rate at each stage.
Results: The proportion of stage I cases was 54% in the 1970’s, and in-
creased to 64% in the 1980’s, 70% in the 1990’s, and 79% since 2000. 
The 5-year survival rate of stage I patients was 58% in the 1970’s, 
and increased to 71% in the 1980’s, 76% in the 1990’s, and 85% since 
2000. The survival index of stage I increased from 32 in the 1970’s, 
to 45 in the 1980’s, 53 in the 1990’s, and 67 since 2000. The stage I 
cases were then sub-classiﬁed in to stage IA and stage IB cases and the 
survival index of the stage IA cases increased from 18 in the 1970’s, 
to 29 in the 1980’s, 39 in the 1990’s, and 53 since 2000. The propor-
tion of stage IA cases detected by a lung cancer mass screening system 
increased from 17% in the 1970’s, to 28% in the 1980’s, 33% in the 
1990’s, and 37% since 2000.
Decade
survival 
rate(%)
Survival index (proportion of cases % × survival rate %)
p-I p-II p-III p-IV
1970-1979
(N=186)
41 32
(54×58)
7
(23×33)
2
(22×10)
0
(1×0)
1980-1989 58 45
(64×71)
8
(16×50%)
5
(20×25)
0
(1×0)(N=630)
1990-1999 63 53
(70×76)
5
(13×42)
5
(18×29)
0
(0×0)(N=1234)
2000-2005 78 67
(79×85)
7
(11×59)
4
(10×36)
0
(0×0)(N=1003)
Conclusion: As the lung cancer mass screening system has come into 
widespread use in Japan, the number of stage IA lung cancer cases 
that have been detected has increased, and because of that the surgical 
results have improved with decades.
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Objectives: To evaluate the compliance with adjuvant chemotherapy 
for completely resected non-small cell lung cancer (NSCLC).
Methods: Between January 2004 and May 2006, the patients with 
ECOG status 0 or 1 who underwent complete resection for NSCLC 
were referred to the oncologists for the adjuvant chemotherapy. Plati-
num-based adjuvant chemotherapy was performed with 3 or 4 cycles 
according to the protocol or the preference by oncologists. 
Results: Two hundred and thirty-two patients were enrolled in the pro-
spective data collection. Median age was 60.9 years and 76.7 % were 
male. Stage IB, II and III were 34.9%, 28.8% and 36.2%, respectively. 
Eleven patients (4.7%) completed one cycle, 8 (3.4%) completed two, 6 
(2.6%) completed three and 142 patients (61.2%) completed all planned 
cycles. Sixty ﬁve patients (28%) received no therapy. The causes of 
start failure for adjuvant chemotherapy consisted of decreased postop-
erative performance status (n=39), refusal such as ﬁnancial problems 
(n=13) and distant metastasis at initial follow up (n=2). The causes 
of cessation during adjuvant chemotherapy were composed of severe 
adverse effects (n=15), aggravation of disease with newly developed 
metastasis (n=4) and others (n=6). The mortality related to the adjuvant 
chemotherapy was 0.86%(n=2) due to pneumonia and sepsis.
Univariate analysis showed that age, postoperative complications and 
the in-hospital duration were the signiﬁcant factors for the completion 
of adjuvant chemotherapy. Preoperative pulmonary function, smoking 
history, surgical extent (lobectomy versus pneumonectomy) and video-
assisted thoracoscopic surgery were not signiﬁcant. Multivariate analy-
sis demonstrated statistically signiﬁcant differences in compliance with 
only age. Increasing age was associated with decreased compliance. 
Mean age was 59 years old in patients with completion of adjuvant 
chemotherapy compared with 64 years old in those who did not achieve 
the satisfactory chemotherapy. 
Conclusion: Adjuvant chemotherapy for completely resected non-
small cell lung cancer is performed with satisfactory compliance 
about 60%. Age plays an important role in the compliance of adjuvant 
chemotherapy. Elderly subsets will be examined to help determine the 
effect of age on compliance and outcome.
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